Table 2.
Characteristics of the patients.
| Reference | Treatment | Child-Pugh | Portal Hypertension Yes (%) | AFP | PVTT Type Ⅰ(%)/Ⅱ(%)/Ⅲ(%)/Ⅳ(%) | HBV (%) | |
|---|---|---|---|---|---|---|---|
| A | B | ||||||
| Hamaoka [15] | SR | 7 | 0 | N/A | 0.321 | N/A; N/A; 3(42.8); 4 (57.1) | 42.8 |
| TACE, RFA, HAIC | 32 | 11 | N/A | N/A; N/A; 18(41.8); 25(58.1) | 32.5 | ||
| p Value | 0.130 | N/A | 0.830 | 0.728 | |||
| Ryon [16] | SR | 12 | 6 | N/A | 0.027 | N/A | 81 |
| TACE, RFA, Y90 radioembolization, systemic therapy | 67 | 85 | N/A | N/A | 83.1 | ||
| p Value | 0.171 | N/A | N/A | 0.750 | |||
| Peng [17] | SR | 197 | 4 | N/A | 0.07 | 27(14.4); 69 (34.3); 83 (41.2); 23(11.4) |
85.5 |
| TACE | 389 | 13 | N/A | 54(13.4); 136(33.8); 166(41.2); 46(11.4) |
88.5 | ||
| p Value | 0.447 | N/A | 1.00 | 0.755 | |||
| Zheng [18] | SR | 75 | 21 | 85.4 | 0.816 | 25(26.0); 23(23.9); 23(23.9; 25(26.0) |
58.3 |
| TACE | 101 | 33 | 88 | 31(23.1); 32(23.8); 33(24.6); 38(28.3) |
5.4 | ||
| p Value | 0.628 | 0.55 | 0.589 | 0.562 | |||
| Kokudo [19] | SR | 1877 | 216 | 12.8 | <0.001 | 893 (42.7); 528 (25.2); 466 (22.3); 206 (9.8) |
29.0 |
| TACE, RFA, HAIC, Systemic therapy | 2512 | 1869 | 41.0 | 879 (20.1); 947 (21.6); 1476 (33.7); 1079 (24.6) |
20.6 | ||
| p Value | 0.001 | N/A | 0.001 | 0.001 | |||
| Tang [20] | SR | 171 | 15 | N/A | 0.031 | 80 (43.0); 66 (35.5); 40 (21.5); N/A |
85.4 |
| RFA+TACE | 169 | 16 | N/A | 72 (38.9); 64 (34.6); 49 (26.5); N/A |
80.5 | ||
| p Value | 0.49 | N/A | 0.687 | 0.513 | |||
| Fan [21] | SR | 18 | 6 | N/A | N/A | N/A | N/A |
| Systemic therapy | 39 | 14 | N/A | N/A | |||
| p Value | 0.351 | N/A | N/A | N/A | |||
| Ye [22] | SR | 84 | 6 | 4.6 | 0.704 | N/A | 13.3 |
| TACE | 78 | 9 | 44.1 | N/A | 20.9 | ||
| p Value | 0.601 | 0.161 | N/A | 0.702 | |||
| Zhang [23] | SR | 28 | 0 | N/A | 0.417 | N/A | 92.8 |
| TACE | 53 | 3 | N/A | N/A | 80.3 | ||
| p Value | 0.457 | N/A | N/A | 0.203 | |||
N/A: Not available.